Robeco Institutional Asset Management B.V. lessened its position in MetLife, Inc. (NYSE:MET - Free Report) by 9.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 89,776 shares of the financial services provider's stock after selling 9,829 shares during the quarter. Robeco Institutional Asset Management B.V.'s holdings in MetLife were worth $7,220,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its stake in shares of MetLife by 7.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 26,488,146 shares of the financial services provider's stock valued at $2,126,734,000 after purchasing an additional 1,824,907 shares during the period. Bank of New York Mellon Corp boosted its position in MetLife by 0.4% in the 1st quarter. Bank of New York Mellon Corp now owns 8,862,835 shares of the financial services provider's stock valued at $711,597,000 after buying an additional 36,177 shares during the period. Ameriprise Financial Inc. grew its stake in shares of MetLife by 3.6% in the first quarter. Ameriprise Financial Inc. now owns 7,406,512 shares of the financial services provider's stock worth $594,410,000 after acquiring an additional 259,993 shares in the last quarter. Northern Trust Corp increased its position in shares of MetLife by 0.8% during the first quarter. Northern Trust Corp now owns 7,109,423 shares of the financial services provider's stock worth $570,816,000 after acquiring an additional 57,221 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in shares of MetLife by 3.7% in the first quarter. Dimensional Fund Advisors LP now owns 6,671,435 shares of the financial services provider's stock valued at $535,568,000 after acquiring an additional 236,698 shares in the last quarter. 94.99% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several research analysts recently commented on the company. Morgan Stanley lowered their target price on MetLife from $98.00 to $94.00 and set an "overweight" rating for the company in a research note on Monday, August 18th. Weiss Ratings restated a "buy (b)" rating on shares of MetLife in a research note on Saturday, September 27th. Keefe, Bruyette & Woods decreased their price target on shares of MetLife from $94.00 to $92.00 and set an "outperform" rating for the company in a research note on Monday, August 11th. Wolfe Research upgraded shares of MetLife to a "strong-buy" rating in a report on Tuesday, September 16th. Finally, Jefferies Financial Group raised their price objective on shares of MetLife from $100.00 to $103.00 and gave the company a "buy" rating in a report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $94.64.
Read Our Latest Stock Report on MET
MetLife Stock Up 1.3%
Shares of NYSE:MET opened at $82.41 on Monday. The firm has a 50 day simple moving average of $79.10 and a 200-day simple moving average of $78.14. MetLife, Inc. has a twelve month low of $65.21 and a twelve month high of $89.05. The company has a current ratio of 0.16, a quick ratio of 0.16 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $54.81 billion, a PE ratio of 13.97, a P/E/G ratio of 0.74 and a beta of 0.86.
MetLife (NYSE:MET - Get Free Report) last posted its earnings results on Wednesday, August 6th. The financial services provider reported $2.02 EPS for the quarter, missing analysts' consensus estimates of $2.32 by ($0.30). MetLife had a net margin of 5.83% and a return on equity of 19.88%. The company had revenue of $17.34 billion during the quarter, compared to analysts' expectations of $18.58 billion. During the same period last year, the business earned $2.28 earnings per share. The company's quarterly revenue was down 2.7% on a year-over-year basis. On average, equities analysts predict that MetLife, Inc. will post 9.65 EPS for the current fiscal year.
MetLife Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 5th were given a $0.5675 dividend. The ex-dividend date of this dividend was Tuesday, August 5th. This represents a $2.27 dividend on an annualized basis and a dividend yield of 2.8%. MetLife's dividend payout ratio is 38.47%.
MetLife Profile
(
Free Report)
MetLife, Inc, a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through six segments: Retirement and Income Solutions; Group Benefits; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements.
See Also
Want to see what other hedge funds are holding MET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MetLife, Inc. (NYSE:MET - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MetLife, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MetLife wasn't on the list.
While MetLife currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here

We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report